E-LIB Suche - Ergebnisse für: Dias, Clapton

1

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-C..:

Liu, Chao ; Lu, Hong ; Yuan, Fei...
Clinical Pharmacology: Advances and Applications. 11 (2019) - p. 145-153 , 2019

Link: https://doi.org/10.2147/..

2

Pharmacokinetics, Safety, and Tolerability of Tezepelumab (..:

Parnes, Jane R. ; Sullivan, John T. ; Chen, Li.
Clinical Pharmacology & Therapeutics. 106 (2019) 2 - p. 441-449 , 2019

Link: https://doi.org/10.1002/..

3

Pharmacokinetics, Pharmacodynamics, and Safety of Single-Do..:

Dias, Clapton ; Moore, Kenneth Todd ; Murphy, Joe...
American Journal of Nephrology. 43 (2016) 4 - p. 229-236 , 2016

Link: https://doi.org/10.1159/..

4

Effect of Rifampin on the Pharmacokinetics of Apixaban, an ..:

Vakkalagadda, Blisse ; Frost, Charles ; Byon, Wonkyung...
American Journal of Cardiovascular Drugs. 16 (2016) 2 - p. 119-127 , 2016

Link: https://doi.org/10.1007/..

5

Effect of ketoconazole and diltiazem on the pharmacokinetic..:

Frost, Charles E. ; Byon, Wonkyung ; Song, Yan...
British Journal of Clinical Pharmacology. 79 (2015) 5 - p. 838-846 , 2015

Link: https://doi.org/10.1111/..

6

Erratum to: Tolerability of High-Volume Subcutaneous Inject..:

Dias, Clapton ; Abosaleem, Bassam ; Crispino, Caroline..
AAPS PharmSciTech. 16 (2015) 6 - p. 1500-1500 , 2015

Link: https://doi.org/10.1208/..

7

Response to 'Inclusion of Placebos and Blinding for Ascendi..:

Ganju, Jitendra ; Dias, Clapton
Basic & Clinical Pharmacology & Toxicology. 117 (2015) 6 - p. 365-366 , 2015

Link: https://doi.org/10.1111/..

8

Tolerability of High-Volume Subcutaneous Injections of a Vi..:

Dias, Clapton ; Abosaleem, Bassam ; Crispino, Caroline..
AAPS PharmSciTech. 16 (2015) 5 - p. 1101-1107 , 2015

Link: https://doi.org/10.1208/..

9

Effects of Evolocumab on Lipoprotein Particles & Subclasses..:

Xu, Ren ; Dias, Clapton ; Peach, Matt...
Journal of Clinical Lipidology. 8 (2014) 3 - p. 350-351 , 2014

Link: https://doi.org/10.1016/..

10

AMG 145, a Fully Human Monoclonal Antibody Against PCSK9, R..:

Shaywitz, Adam J. ; Dias, Clapton ; Smith, Brian...
Journal of Clinical Lipidology. 6 (2012) 3 - p. 286-287 , 2012

Link: https://doi.org/10.1016/..

11

Rationale for Sponsor-unblinded Phase 1 Trials: Challenging..:

Ganju, Jitendra ; Dias, Clapton
Drug Information Journal. 44 (2010) 1 - p. 21-27 , 2010

Link: https://doi.org/10.1177/..

12

Corneal Permeation of Ganciclovir: Mechanism of Ganciclovir..:

Tirucherai, Giridhar S. ; Dias, Clapton ; Mitra, Ashim K.
Journal of Ocular Pharmacology and Therapeutics. 18 (2002) 6 - p. 535-548 , 2002

Link: https://doi.org/10.1089/..

13

Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK..:

Gibbs, John P. ; Slatter, J. Greg ; Egbuna, Ogo...
The Journal of Clinical Pharmacology. 57 (2016) 4 - p. 513-523 , 2016

Link: https://doi.org/10.1002/..

14

Effect of Mono‐ and Di‐acylation on the Ocular Disposition ..:

Dias, Clapton S. ; Anand, Banmeet S. ; Mitra, Ashim K.
Journal of Pharmaceutical Sciences. 91 (2002) 3 - p. 660-668 , 2002

Link: https://doi.org/10.1002/..

15

Vitreal Elimination Kinetics of Large Molecular Weight FITC..:

Dias, Clapton S. ; Mitra, Ashim K.
Journal of Pharmaceutical Sciences. 89 (2000) 5 - p. 572-578 , 2000

Link: https://doi.org/10.1002/..